mmhce

I find 10% to 30% non-viability of grafts extremely high!!

Any further comments on this quantity?

Bill..anyone?

Isn't Accutane a derivative of Vitamin A and should the consumption of food stuff containing high quantities of Vitamin A be avoided prior to hair transplant surgery?

Additionally should the use of spironolactone laced with Retin-A be avoided prior to and after hair transplant surgery?

Isn't it true that on average 7-8 grafts per 1000 will be lost?

He was a black guy, and wound up with virtually no detectable scar

This raises another issue, that I am not sure is dealt with in other threads.

Is the appearance of scar tissue on a person of colour, more distinct/unsightly, than a Caucasian, after they have had hair transplant surgery?

"and the scar potentials associated therein."

Is it that, the wider the extracted strip, the greater the scar tissue?

Yes this seems irregular.

"Two were very difficult and decided to hold off on those two for 10 days when we remove the other half."

Shouldn't all the staples be removed at the same time?

Wouldn't tissue begin to grow over the staples if they are not removed at the stipulated 10-12 period and thus be even more painful/difficult to remove?

"medicolegally, we could become responsible for your other doc's work."

That is what I was referring to in this thread:

http://hair-restoration-info.com/eve/forums/a/tpc/f/346...681076304#6681076304

when I said:

"Is this because the suturing/stapling was not their handy work and they do not want to accept "responsibility" for any "perceived" low quality of such stapling or damage done in removing the stapling?"

Thanks Bill,

1.Correct me if I am wrong, but isn't the amount of grafts lost after surgery is usually less than 1%?

2.But how many cases have been recorded of large scale loss of transplanted grafts, if any?

3.And how much does this represent statistically in relation to the amount of sucessful hair transplant surgeries?

Thanks,take care...

"I've stopped losing any grafts"

Forgive if I am wrong, but I think you are referring to the hair shaft itself going into telogen when you said that you were losing grafts.

I am referring to the infant mortality of the grafts itself after they have been transplanted,(necrosis of tissue, rather than fusion of the graft to the recepient tissue) not the effluvium of hair.

What might be the key causes of transplant grafts not to grow in the recepient area?

(Substance abuse, idiosyncrastic poor healing factors/abilities of a patient, etc.)

Have there ever been any recorded cases of rejection(on a large scale) of the transplanted grafts in the recepient area?

(Not considering the small percentage of transplanted grafts that die permanently after transplantation.)

What might be the key causes of transplant grafts not to grow in the recepient area?

(Substance abuse, idiosyncrastic poor healing factors/abilities of a patient, etc.)

Have there ever been any recorded cases of rejection(on a large scale) of the transplanted grafts in the recepient area?

(Not considering the small percentage of transplanted grafts that die permanently after transplantation.)

Thanks.

Question closed.

That's not what a lot of other people say:

http://hair-restoration-info.com/eve/forums?a=tpc&f=346...461076304#2461076304

Thanks for the reassuring comments.

Question remains open....

Doctors usually recommend to suspend all medication 5 days prior to surgery.

Is it acceptable to use suppositories in the days prior to the hair transplant surgery?

What about Daflon?

See Daflon Drug Information here:

DAFLON DRUG INFORMATION

Content Micronized purified flavonoidic fraction (diosmin 450 mg, hesperidin 50 mg).

Description Each tablet contains micronized flavonoid fraction 500 mg (diosmin 450 mg and hesperidin 50 mg).

Daflon 500 also contains the following excipients: Carboxymethylcellulose sodium, microcrystalline cellulose, gelatin, magnesium stearate, talc, white beeswax, glycerol, hydroxypropylmethylcellulose (2910), polyethylene glycol 6000, sodium lauryl sulfate, yellow iron oxide, red iron oxide and titanium dioxide.

The innovation with Daflon 500 consists of the micronization of its active constituent from particles of 30-60 microns to particles of <2 microns. This new and optimized form allows Daflon 500 to increase venous tone from the first 2-tab dose and by the 1st hour and provides Daflon 500 with added clinical efficacy.

Actions Daflon 500 is a phlebotonic drug and a vascular protecting agent.

The efficacy of Daflon 500 is accounted for by its specific action on the principal elements of venous disease.

Daflon 500 is phlebotonic: It reinforces venous tone by prolonging the activity of parietal noradrenaline. Thus, Daflon 500 decreases venous capacitance, venous distensibility and venous emptying time.

Daflon 500 protects the microcirculation by fighting the microcirculation-damaging process; it combats venous inflammation by decreasing leukocyte activation, and as a consequence, by inhibiting the release of inflammatory mediators, principally free radicals and prostaglandins. Thus, Daflon 500 normalizes capillary permeability and strengthens capillary resistance.

Daflon 500 acts on the lymphatic system: It improves lymphatic drainage by increasing lymph flow and lymph oncotic pressure. This action on the lymphatic system associated with a phlebotonic and vasculoprotective effect, explains the activity of Daflon 500 on CVI-associated edema.

Double-blind, placebo-controlled studies have demonstrated Daflon 500's efficacy on chronic venous insufficiency. Daflon 500 significantly improves disabling symptoms of venous insufficiency which affect everyday active life: Heavy legs, pain, heat sensation, edema, functional impairment, nocturnal cramps and restless legs.

In addition to conventional compression therapy, Daflon 500 has also demonstrated to cure 3 times as many venous leg ulcers as placebo, and to accelerate their complete healing.

Daflon 500 is highly effective in the treatment of chronic hemorrhoidal disease. It significantly improves subjective symptoms and objective signs, eg anal discomfort, pain, redness, anal discharge, proctitis, tenesmus, pruritus, erythema and bleeding. Daflon 500 also significantly reduces the frequency, severity and duration of acute hemorrhoidal attacks.

Indication Organic & functional chronic venous insufficiency of the lower limbs; heavy legs, pain, nocturnal cramps. Hemorrhoidal disease, acute hemorrhoidal attacks.

Dosage Chronic venous insufficiency 2 tab daily. Acute hemorrhoidal attacks 6 tab/day for the 1st 4 days, then 4 tab/day for 3 days, 2 tab thereafter. Chronic hemorrhoids 2 tab daily.

Special Precaution Lactation.

Adverse Reaction Minor GI & neurovegetative disorders.

Doctors usually recommend to suspend all medication 5 days prior to surgery.

Is it acceptable to use suppositories in the days prior to the hair transplant surgery?

What about Daflon?

See Daflon Drug Information here:

DAFLON DRUG INFORMATION

Content Micronized purified flavonoidic fraction (diosmin 450 mg, hesperidin 50 mg).

Description Each tablet contains micronized flavonoid fraction 500 mg (diosmin 450 mg and hesperidin 50 mg).

Daflon 500 also contains the following excipients: Carboxymethylcellulose sodium, microcrystalline cellulose, gelatin, magnesium stearate, talc, white beeswax, glycerol, hydroxypropylmethylcellulose (2910), polyethylene glycol 6000, sodium lauryl sulfate, yellow iron oxide, red iron oxide and titanium dioxide.

The innovation with Daflon 500 consists of the micronization of its active constituent from particles of 30-60 microns to particles of <2 microns. This new and optimized form allows Daflon 500 to increase venous tone from the first 2-tab dose and by the 1st hour and provides Daflon 500 with added clinical efficacy.

Actions Daflon 500 is a phlebotonic drug and a vascular protecting agent.

The efficacy of Daflon 500 is accounted for by its specific action on the principal elements of venous disease.

Daflon 500 is phlebotonic: It reinforces venous tone by prolonging the activity of parietal noradrenaline. Thus, Daflon 500 decreases venous capacitance, venous distensibility and venous emptying time.

Daflon 500 protects the microcirculation by fighting the microcirculation-damaging process; it combats venous inflammation by decreasing leukocyte activation, and as a consequence, by inhibiting the release of inflammatory mediators, principally free radicals and prostaglandins. Thus, Daflon 500 normalizes capillary permeability and strengthens capillary resistance.

Daflon 500 acts on the lymphatic system: It improves lymphatic drainage by increasing lymph flow and lymph oncotic pressure. This action on the lymphatic system associated with a phlebotonic and vasculoprotective effect, explains the activity of Daflon 500 on CVI-associated edema.

Double-blind, placebo-controlled studies have demonstrated Daflon 500's efficacy on chronic venous insufficiency. Daflon 500 significantly improves disabling symptoms of venous insufficiency which affect everyday active life: Heavy legs, pain, heat sensation, edema, functional impairment, nocturnal cramps and restless legs.

In addition to conventional compression therapy, Daflon 500 has also demonstrated to cure 3 times as many venous leg ulcers as placebo, and to accelerate their complete healing.

Daflon 500 is highly effective in the treatment of chronic hemorrhoidal disease. It significantly improves subjective symptoms and objective signs, eg anal discomfort, pain, redness, anal discharge, proctitis, tenesmus, pruritus, erythema and bleeding. Daflon 500 also significantly reduces the frequency, severity and duration of acute hemorrhoidal attacks.

Indication Organic & functional chronic venous insufficiency of the lower limbs; heavy legs, pain, nocturnal cramps. Hemorrhoidal disease, acute hemorrhoidal attacks.

Dosage Chronic venous insufficiency 2 tab daily. Acute hemorrhoidal attacks 6 tab/day for the 1st 4 days, then 4 tab/day for 3 days, 2 tab thereafter. Chronic hemorrhoids 2 tab daily.

Special Precaution Lactation.

Adverse Reaction Minor GI & neurovegetative disorders.

Yes....but is it ok inject?

For those who choose to go to a physican for the removal of the metal staples in the donor area, is it ok to have a physician inject a local anaesthetic to the donor area before removing the staples to relieve the pain?

Bearing in mind that there is a greater risk of the anaesthetic being systemically absorbed if the wound is not entirely healed.

For those who choose to go to a physican, is it ok to have a physician inject a local anaesthetic to the donor area before removing the staples to relieve the pain?

Bearing in mind that there is a greater risk of the anaesthetic being systemically absorbed if the wound is not entirely healed.

Bill is right. The only sure way to tell at your stage is under magnification. You need greater hair loss that this, to have greater confidence that it might be MPB. The pictures don't look that bad. If it MPB, start on finasteride and minoxidil for the crown.

Thanks!

Maybe I"ll get the book too.

take care...

that the majority of patients will need/want more than one in their lifetime

This is true and I had asked a question(s) on the forum, found here:

http://hair-restoration-info.com/eve/forums/a/tpc/f/504...121023304#9121023304

such as:

1. What does a well done hair transplant, done by the best surgeon look like if no continued surgical intervention is done to maintain the illusion of density ?

2. If the patient does decide, not to pursue further surgical interventions, does the hair transplant stand the test of time? Does the scalp look patchy after the native hair has miniaturized to point of pre-vellus diameter?

3. Does the patient grow wary of having to do follow-up surgeries to always maintain the illusion of density?

4. At what point may the patient accept that the time has come to "call it quits" and stop chasing the illusion of density?

5. Does this come when chronic physiological diseases such as diabetes, heart disease, arthritis begin to occur, or perhaps other life threatening diseases?

6.Perhaps this might be a totally personal decision on the part of the patient as to "how young they feel" and how young they want to look?

Any comments Bill?

take care,

Dr. Unger has co-authored this book:

http://www.amazon.com/Hair-Transplantation-Fourth-Walter-Unger/dp/0824741102/ref=sr_1_1?ie=UTF8&s=books&qid=1226836452&sr=1-1

with Ron Shapiro, and is known by the member Aquarius, on this thread:

http://hair-restoration-info.com/eve/forums/a/tpc/f/746...091002623#6091002623

but is not recommended on the Coaltion List.

Why is this?

It occurs to me that the issues of direct post-operative outcomes are dealt with on the forum, but the advancement of alopecia even after surgical intervention is not dealt with as much.

(If I did not find a the thread that deals with such issues, please refer me.)

After the hair transplant surgery, and there has been renewed growth in the scalp, the native hair does continue to miniaturize even with medication and at a retarded rate.

My question is:

1. What does a well done hair transplant, done by the best surgeon look like if no continued surgical intervention is done to maintain the illusion of density ?

2. If the patient does decide, not to pursue further surgical interventions, does the hair transplant stand the test of time? Does the scalp look patchy after the native hair has miniaturized to point of pre-vellus diameter?

3.Can the transplanted hair age naturally along side the native hair,to give a blended overall natural thinning look and not a patchy appearance?

4. Generally how is placement of the transplanted hair done in relation the native hair within the atrophic zone?

5. Does the patient grow wary of having to do follow-up surgeries to always maintain the illusion of density?

6. At what point may the patient accept that the time has come to "call it quits" and stop chasing the illusion of density?

7. Does this come when chronic physiological diseases such as diabetes, heart disease, arthritis begin to occur, or perhaps other life threatening diseases?

Perhaps this might be a totally personal decision on the part of the patient as to "how young they feel" and how young they want to look?

Thanks.

When a surgeon guarantees for a patient, a certain density of X FU/cm2 after surgery , does this quote of X FU/cm2 include the count of the native hair on the scalp?

Shouldn't a quote of X Fu/cm2 only count the transplanted hair?

Thanks.